{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T17:42:03Z","timestamp":1789062123339,"version":"build-2803163510"},"update-to":[{"DOI":"10.1002\/14651858.cd008605.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T00:00:00Z","timestamp":1618358400000}}],"reference-count":111,"publisher":"Wiley","issue":"4","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd008605.pub4","type":"journal-article","created":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T08:27:06Z","timestamp":1618388826000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Dopamine agonists for preventing ovarian hyperstimulation syndrome"],"prefix":"10.1002","volume":"2021","author":[{"given":"Huilin","family":"Tang","sequence":"additional","affiliation":[{"name":"Institute for Drug Evaluation; Peking University Health Science Center; Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selma M.","family":"Mourad","sequence":"additional","affiliation":[{"name":"Radboud University Medical Centre; Nijmegen Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aihua","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy; Beijing Obstetrics and Gynecology Hospital, Capital Medical University; Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suo-Di","family":"Zhai","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Therapeutic Drug Monitoring and Clinical Toxicology Center of Peking University; Peking University Third Hospital; Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger J","family":"Hart","sequence":"additional","affiliation":[{"name":"School of Women's and Infants' Health; The University of Western Australia, King Edward Memorial Hospital and Fertility Specialists of Western Australia; Subiaco, Perth Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,4,14]]},"reference":[{"issue":"3 Suppl 1","key":"10.1002\/14651858.CD008605.pub4-BIB0001|cit1","first-page":"S103","article-title":"Role of quinagolide (Norprolac) in preventing ovarian hyperstimulation syndrome (OHSS) in high risk intracytoplasmic sperm injection (ICSI) patients","volume":"98","author":"Alhalabi","year":"2010","journal-title":"Fertility and Sterility"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008605.pub4-BIB0002|cit2","first-page":"P","article-title":"Quinagolide reduces OHSS in high risk ICSI patients","volume":"26","author":"Alhalabi","year":"2011","journal-title":"Human Reproduction"},{"issue":"1","key":"10.1002\/14651858.CD008605.pub4-BIB0003|cit3","first-page":"i74","article-title":"Cabergoline versus calcium gluconate infusion in the prevention of ovarian hyperstimulation syndrome. A randomized controlled trial","volume":"34","author":"El-Shaer","year":"2019","journal-title":"Human Reproduction"},{"key":"10.1002\/14651858.CD008605.pub4-BIB0004|cit4","first-page":"i96","article-title":"The dopamine agonist cabergoline prevents moderate-severe early ovarian hyperstimulation syndrome (OHSS) in high-risk ART patients","volume":"21","author":"Alvarez","year":"2006","journal-title":"Human Reproduction"},{"key":"10.1002\/14651858.CD008605.pub4-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1210\/jc.2007-0409","article-title":"Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction","volume":"92","author":"Alvarez","year":"2007","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"1-2","key":"10.1002\/14651858.CD008605.pub4-BIB0006|cit6","first-page":"48","article-title":"Cabergoline for reducing ovarian hyperstimulation syndrome in assisted reproductive technology treatment cycles. A prospective randomized controlled trial","volume":"60","author":"Amir","year":"2015","journal-title":"Journal of Reproductive Medicine"},{"issue":"4","key":"10.1002\/14651858.CD008605.pub4-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1016\/j.fertnstert.2011.07.325","article-title":"Can dopamine agonist cabergoline reduce ovarian hyperstimulation syndrome in ART treatment cycles? A prospective randomized study","volume":"95","author":"Amir","year":"2011","journal-title":"Fertility and Sterility"},{"issue":"2","key":"10.1002\/14651858.CD008605.pub4-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/ijgo.12360","article-title":"Randomized trial of combined cabergoline and coasting in preventing ovarian hyperstimulation syndrome during in vitro fertilization\/intracytoplasmic sperm injection cycles","volume":"140","author":"Bassiouny Yasmin","year":"2018","journal-title":"International Journal of Gynaecology and Obstetrics"},{"issue":"3","key":"10.1002\/14651858.CD008605.pub4-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3109\/09513590.2012.736554","article-title":"The effects of bromocriptine on VEGF, kidney function and ovarian hyperstimulation syndrome in in vitro fertilization patients: a pilot study","volume":"29","author":"Beltrame","year":"2013","journal-title":"Gynecological Endocrinology"},{"issue":"4","key":"10.1002\/14651858.CD008605.pub4-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/humrep\/deq005","article-title":"The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial","volume":"25","author":"Busso","year":"2010","journal-title":"Human Reproduction"},{"key":"10.1002\/14651858.CD008605.pub4-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/S1472-6483(10)60401-4","article-title":"Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study","volume":"17","author":"Carizza","year":"2008","journal-title":"Reproductive Biomedicine Online"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008605.pub4-BIB0012|cit12","first-page":"i141","article-title":"Ongoing clinical pregnancy is not affected by cabergoline use in women undergoing ICSI with estradiol levels beyond 4000 pg\/ml on the day of the hCG","volume":"23","author":"Carizza","year":"2008","journal-title":"Human Reproduction"},{"key":"10.1002\/14651858.CD008605.pub4-BIB0013|cit13","first-page":"78","article-title":"Comparison of coasting with cabergoline administration for prevention of early severe OHSS","volume":"121","author":"Dalal","year":"2014","journal-title":"BJOG"},{"issue":"4","key":"10.1002\/14651858.CD008605.pub4-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.mefs.2018.05.001","article-title":"Comparison of cabergoline versus calcium infusion in ovarian hyperstimulation syndrome prevention: a randomized clinical trial","volume":"23","author":"Elnory","year":"2018","journal-title":"Middle East Fertility Society Journal"},{"key":"10.1002\/14651858.CD008605.pub4-BIB0015|cit15","first-page":"i74","article-title":"Cabergoline versus calcium gluconate infusion in the prevention of ovarian hyperstimulation syndrome. A randomized controlled trial","volume":"34","author":"El-Shaer","year":"2019","journal-title":"Human Reproduction"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008605.pub4-BIB0016|cit16","first-page":"P","article-title":"Effects of cabergoline administration for the prevention of OHSS upon the levels of VEGF, VEGFR-1 and VEGFR-2 in high risk IVF\/ICSI patients","volume":"29","author":"Fetisova","year":"2014","journal-title":"Human Reproduction"},{"issue":"7","key":"10.1002\/14651858.CD008605.pub4-BIB0017|cit17","first-page":"693","article-title":"Evaluation of intravenous hydroxyethyl starch, intravenous albumin 20% and oral cabergoline for prevention of ovarian hyperstimulation syndrome in patients undergoing ovulation induction","volume":"20","author":"Ghahiri","year":"2015","journal-title":"Journal of Research in Medical Sciences"},{"issue":"6","key":"10.1002\/14651858.CD008605.pub4-BIB0018|cit18","first-page":"4","article-title":"Evaluation of three different strategies (intravenous hydroxyl ethyl starch, intravenous albumin 20%, and oral cabergoline) for prevention of ovarian hyperstimulation syndrome in patients undergoing ovulation induction","volume":"12","author":"Ghahiri","year":"2014","journal-title":"Iranian Journal of Reproductive Medicine"},{"key":"10.1002\/14651858.CD008605.pub4-BIB0019|cit19","doi-asserted-by":"crossref","unstructured":"Jellad S Haj Hassine A Basly M Mrabet A Chibani M Rachdi R Vascular endothelial growth factor antagonist reduces the early onset and the severity of ovarian hyperstimulation syndrome Journal de Gyn\u00e9cologie, Obst\u00e9trique et Biologie de la Reproduction 2017 46 1 87 91","DOI":"10.1016\/j.jgyn.2016.04.002"},{"key":"10.1002\/14651858.CD008605.pub4-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"123","DOI":"10.4103\/2231-0770.165121","article-title":"Cabergoline for preventing ovarian hyperstimulation syndrome in women at risk undergoing in vitro fertilization\/intracytoplasmic sperm injection treatment cycles: a randomized controlled study","volume":"5","author":"Kilic","year":"2015","journal-title":"Avicenna Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD008605.pub4-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ejogrb.2013.07.010","article-title":"Prevention of ovarian hyperstimulation syndrome in GnRH agonist IVF cycles in moderate risk patients: randomized study comparing hydroxyethyl starch versus cabergoline and hydroxyethyl starch","volume":"170","author":"Matorras","year":"2013","journal-title":"European Journal of Obstetrics and Gynecology and Reproductive Biology"},{"issue":"3","key":"10.1002\/14651858.CD008605.pub4-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.mefs.2017.02.004","article-title":"Diosmin versus cabergoline for prevention of ovarian hyperstimulation syndrome","volume":"22","author":"Saad","year":"2017","journal-title":"Middle East Fertility Society Journal"},{"issue":"2","key":"10.1002\/14651858.CD008605.pub4-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/01.EBX.0000413115.90725.a7","article-title":"Can cabergoline prevent ovarian hyperstimulation syndrome in polycystic ovarian patients undergoing gonadotropin stimulation?","volume":"2","author":"Salah","year":"2012","journal-title":"Evidence Based Women's Health Journal"},{"issue":"1","key":"10.1002\/14651858.CD008605.pub4-BIB0024|cit24","first-page":"i60","article-title":"Can cabergoline prevent ovarian hyperstimulation syndrome in PCO patients undergoing gonadotropin stimulation? Comparative study with prednisolone","volume":"24","author":"Salah Edeen","year":"2009","journal-title":"Human Reproduction"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008605.pub4-BIB0025|cit25","first-page":"O","article-title":"Role of cabergoline in preventing ovarian hyperstimulation syndrome in high risk intracytoplasmic sperm injection (ICSI) patients and effect on outcome","volume":"24","author":"Shaltout","year":"2009","journal-title":"Human Reproduction"},{"issue":"2","key":"10.1002\/14651858.CD008605.pub4-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ejogrb.2012.08.008","article-title":"Can dopamine agonist at a low dose reduce ovarian hyperstimulation syndrome in women at risk undergoing ICSI treatment cycles? A randomized controlled study","volume":"165","author":"Shaltout","year":"2012","journal-title":"European Journal of Obstetrics, Gynecology, and Reproductive Biology"},{"issue":"2","key":"10.1002\/14651858.CD008605.pub4-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"54","DOI":"10.5005\/jp-journals-10016-1149","article-title":"Efficacy of cabergoline in the prevention of ovarian hyperstimulation syndrome: a randomized, double-blind and placebo-controlled trial","volume":"8","author":"Singh","year":"2017","journal-title":"International Journal of Infertility and Fetal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD008605.pub4-BIB0028|cit28","first-page":"35","article-title":"Cabergoline versus coasting in the prevention of ovarian hyperstimulation syndrome and assisted reproductive technologies outcome in high risk patients","volume":"3","author":"Sohrabvand","year":"2009","journal-title":"International Journal of Fertility and Sterility"},{"issue":"3","key":"10.1002\/14651858.CD008605.pub4-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s10815-011-9708-4","article-title":"Comparison of cabergoline and intravenous albumin in the prevention of ovarian hyperstimulation syndrome: a randomized clinical trial","volume":"29","author":"Tehraninejad","year":"2012","journal-title":"Journal of Assisted Reproduction and Genetics"},{"issue":"10","key":"10.1002\/14651858.CD008605.pub4-BIB0030|cit30","first-page":"837","article-title":"Comparison of albumin and cabergoline in the prevention of ovarian hyperstimulation syndrome: a clinical trial study","volume":"11","author":"Torabizadeh","year":"2013","journal-title":"Iranian Journal of Reproductive Medicine"},{"issue":"2","key":"10.1002\/14651858.CD008605.pub4-BIB0031|cit31","first-page":"51","article-title":"Comparison of coasting with cabergoline administration for prevention of early severe OHSS in ART cycles","volume":"6","author":"Aflatoonian","year":"2008","journal-title":"Iranian Journal of Reproductive Medicine"},{"key":"10.1002\/14651858.CD008605.pub4-BIB0032|cit32","first-page":"70","article-title":"Cabergoline for prevention of ovarian hyperstimulation syndrome in high risk patients","volume":"8","author":"Agha Hosseini","year":"2010","journal-title":"Iranian Journal of reproductive Medicine"},{"key":"10.1002\/14651858.CD008605.pub4-BIB0033|cit33","first-page":"3210","article-title":"Implantation is apparently unaffected by the dopamine agonist cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study","volume":"22","author":"Alvarez","year":"2007","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"3","key":"10.1002\/14651858.CD008605.pub4-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1168.e1","DOI":"10.1016\/j.fertnstert.2009.05.021","article-title":"High dose cabergoline in management of ovarian hyperstimulation syndrome","volume":"92","author":"Ata","year":"2009","journal-title":"Fertility and Sterility"},{"issue":"1","key":"10.1002\/14651858.CD008605.pub4-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13048-016-0237-8","article-title":"GnRH antagonist rescue protocol combined with cabergoline versus cabergoline alone in the prevention of ovarian hyperstimulation syndrome: a randomized controlled trial","volume":"9","author":"Fouda","year":"2016","journal-title":"Journal of Ovarian Research"},{"issue":"184","key":"10.1002\/14651858.CD008605.pub4-BIB0036|cit36","first-page":"1","article-title":"Comparison of the effect of letrozole versus cabergoline for prevention of ovarian hyperstimulation syndrome (OHSS) in patients under ovulation induction treatments and IVF cycles","volume":"18","author":"Ghaebi","year":"2016","journal-title":"Iranian Journal of Obstetrics, Gynecology and Infertility"},{"issue":"4","key":"10.1002\/14651858.CD008605.pub4-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"S259","DOI":"10.1016\/j.fertnstert.2011.07.994","article-title":"The effects of cabergoline on ovarian hyperstimulation syndrome (OHSS) and pregnancy outcomes on in vitro fertilization (IVF) patients","volume":"95","author":"Gualtieri","year":"2011","journal-title":"Fertility and Sterility"},{"issue":"4","key":"10.1002\/14651858.CD008605.pub4-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"S180","DOI":"10.1016\/j.fertnstert.2010.07.705","article-title":"The effect of cabergoline on follicular microenvironment profile in patients with high risk of OHSS","volume":"94","author":"Guvendag","year":"2010","journal-title":"Fertility and Sterility"},{"issue":"s1","key":"10.1002\/14651858.CD008605.pub4-BIB0039|cit39","first-page":"16","article-title":"Cabergoline does not appear to affect pregnancy rates in patients undergoing assisted reproduction","volume":"15","author":"Hatton","year":"2012","journal-title":"Human Fertility"},{"issue":"3","key":"10.1002\/14651858.CD008605.pub4-BIB0040|cit40","first-page":"207","article-title":"The effectiveness of cabergoline for the prevention of ovarian hyperstimulation syndrome","volume":"36","author":"Hosseini","year":"2011","journal-title":"Iranian Journal of Medical Science"},{"issue":"5","key":"10.1002\/14651858.CD008605.pub4-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/j.fertnstert.2010.01.096","article-title":"Cabergoline and ganirelix therapy for early moderate to severe ovarian hyperstimulation syndrome (OHSS) results in faster recovery than in early untreated OHSS","volume":"93","author":"Khan","year":"2010","journal-title":"Fertility and Sterility"},{"issue":"4","key":"10.1002\/14651858.CD008605.pub4-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"248","DOI":"10.4103\/0974-1208.126293","article-title":"Calcium gluconate infusion is as effective as the vascular endothelial growth factor antagonist cabergoline for the prevention of ovarian hyperstimulation syndrome","volume":"6","author":"Naredi","year":"2013","journal-title":"Journal of Human Reproductive Sciences"},{"issue":"3","key":"10.1002\/14651858.CD008605.pub4-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"1169.e15","DOI":"10.1016\/j.fertnstert.2009.05.062","article-title":"Treatment of ovarian hyperstimulation syndrome using a dopamine agonist and gonadotropin releasing hormone antagonist: a case series","volume":"92","author":"Rollene","year":"2009","journal-title":"Fertility and Sterility"},{"issue":"3","key":"10.1002\/14651858.CD008605.pub4-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"S240","DOI":"10.1016\/j.fertnstert.2009.07.1598","article-title":"Cabergoline and ganirelix treatment of ovarian hyperstimulation syndrome (OHSS) results in rapid clinical improvement","volume":"92","author":"Rollene","year":"2009","journal-title":"Fertility and Sterility"},{"issue":"Supp 1","key":"10.1002\/14651858.CD008605.pub4-BIB0045|cit45","first-page":"P","article-title":"Calcium dobesilate versus cabergoline for prevention of ovarian hyperstimulation syndrome","volume":"31","author":"Saad","year":"2016","journal-title":"Human Reproduction"},{"key":"10.1002\/14651858.CD008605.pub4-BIB0046|cit46","first-page":"200","article-title":"Diosmin addition to cabergoline for the prevention of OHSS, will it differ? A pilot study","volume":"126","author":"Saad","year":"2019","journal-title":"BJOG"},{"issue":"6","key":"10.1002\/14651858.CD008605.pub4-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.rbmo.2013.03.002","article-title":"Clinical outcome according to timing of cabergoline initiation for prevention of OHSS: a randomized controlled trial","volume":"26","author":"Seow","year":"2013","journal-title":"Reproductive Biomedicine Online"},{"issue":"7","key":"10.1002\/14651858.CD008605.pub4-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1080\/09513590.2018.1425989","article-title":"Laparoscopic ovarian drilling versus GnRH antagonist combined with cabergoline as a prophylaxis against the re-development of ovarian hyperstimulation syndrome","volume":"34","author":"Seyam","year":"2018","journal-title":"Gynecological Endocrinology"},{"issue":"2","key":"10.1002\/14651858.CD008605.pub4-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"85","DOI":"10.4103\/0974-1208.69342","article-title":"Effect of bromocriptine on the severity of ovarian hyperstimulation syndrome and outcome in high responders undergoing assisted reproduction","volume":"3","author":"Sherwal","year":"2010","journal-title":"Journal of Human Reproductive Sciences"},{"issue":"1","key":"10.1002\/14651858.CD008605.pub4-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.mefs.2010.10.004","article-title":"Cabergoline vs intravenous albumin or combination of both for prevention of the early onset ovarian hyperstimulation syndrome","volume":"16","author":"Soliman","year":"2011","journal-title":"Middle East Fertility Society Journal"},{"issue":"8","key":"10.1002\/14651858.CD008605.pub4-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1016\/j.fertnstert.2011.02.032","article-title":"Dopamine agonist bromocriptine for the prevention of ovarian hyperstimulation syndrome","volume":"95","author":"Spitzer","year":"2011","journal-title":"Fertility and Sterility"},{"issue":"3","key":"10.1002\/14651858.CD008605.pub4-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.mefs.2017.12.008","article-title":"Clomiphene citrate plus cabergoline versus clomiphene citrate for induction of ovulation in infertile euprolactinemic patients with polycystic ovary syndrome: a randomized clinical trial","volume":"23","author":"Zahran","year":"2018","journal-title":"Middle East Fertility Society Journal"},{"issue":"2","key":"10.1002\/14651858.CD008605.pub4-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3923\/rjog.2011.51.58","article-title":"Comparison of the clinical efficacy of two different cabergoline regimens on prevention of ovarian hyperstimulation syndrome (OHSS)","volume":"4","author":"Zargar","year":"2011","journal-title":"Research Journal of Obstetrics and Gynecology"},{"key":"10.1002\/14651858.CD008605.pub4-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/S1472-6483(10)62518-7","article-title":"Cabergoline versus human albumin in prophylaxis of ovarian hyperstimulation syndrome","volume":"20","author":"Ahmadi","year":"2010","journal-title":"Reproductive Biomedicine Online"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008605.pub4-BIB0055|cit55","first-page":"6 Abstract O","article-title":"Cabergoline versus human albumin in prophylaxis of ovarian hyperstimulation syndrome","volume":"9","author":"Ahmadi","year":"2011","journal-title":"Iranian Journal of Reproductive Medicine"},{"key":"10.1002\/14651858.CD008605.pub4-BIB0056|cit56","unstructured":"Comparative study between cabergoline and intravenous calcium in the prevention of ovarian hyperstimulation in women with polycystic ovarian disease undergoing intracytoplasmic sperm injection (ICSI)"},{"key":"10.1002\/14651858.CD008605.pub4-BIB0057|cit57","unstructured":"Study of cabergoline for prevention of ovarian hyperstimulation syndrome (OHSS) in in vitro fertilization cycles and derivation of OHSS biomarkers"},{"key":"10.1002\/14651858.CD008605.pub4-BIB0058|cit58","unstructured":"Effects of calcium in the prevention of ovarian hyperstimulation syndrome in patients undergoing IVF\/ICSI"},{"key":"10.1002\/14651858.CD008605.pub4-BIB0059|cit59","unstructured":"Effect of cabergoline on endometrial vascularity during intracytoplasmic sperm injection"},{"key":"10.1002\/14651858.CD008605.pub4-BIB0060|cit60","unstructured":"Diosmin versus cabergoline for prevention of ovarian hyperstimulation syndrome (infertility)"},{"issue":"3","key":"10.1002\/14651858.CD008605.pub4-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/humupd\/dmg018","article-title":"Ovarian hyperstimulation syndrome: classifications and critical analysis of preventive measures","volume":"9","author":"Aboulghar","year":"2003","journal-title":"Human Reproduction Update"},{"issue":"1","key":"10.1002\/14651858.CD008605.pub4-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S1472-6483(10)60043-0","article-title":"Symposium: update on prediction and management of OHSS - prevention of OHSS","volume":"19","author":"Aboulghar","year":"2009","journal-title":"Reproductive Biomedicine Online"},{"issue":"5","key":"10.1002\/14651858.CD008605.pub4-BIB0063|cit63","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001750.pub3","article-title":"Gonadotrophin-releasing hormone antagonists for assisted reproductive technology","author":"Al-Inany","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD008605.pub4-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3109\/14647273.2013.833348","article-title":"Do dopamine agonists prevent or reduce the severity of ovarian hyperstimulation syndrome in women undergoing assisted reproduction? A systematic review and meta-analysis","volume":"16","author":"Baumgarten","year":"2013","journal-title":"Human Fertility (Cambridge)"},{"key":"10.1002\/14651858.CD008605.pub4-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12902-020-0507-8","article-title":"Cardiac valvular abnormalities associated with use and cumulative exposure of cabergoline for hyperprolactinemia: the CATCH study","volume":"20","author":"Budayr","year":"2020","journal-title":"BMC Endocrine Disorders"},{"issue":"1","key":"10.1002\/14651858.CD008605.pub4-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1472-6483(10)60044-2","article-title":"Symposium: update on prediction and management of OHSS: prevention of OHSS - dopamine agonists","volume":"19","author":"Busso","year":"2009","journal-title":"Reproductive Biomedicine Online"},{"issue":"12","key":"10.1002\/14651858.CD008605.pub4-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1210\/jc.2015-3676","article-title":"Reducing the risk of OHSS by GnRH agonist triggering","volume":"100","author":"Casper","year":"2015","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"2","key":"10.1002\/14651858.CD008605.pub4-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1472-6483(10)60065-X","article-title":"Ovarian hyperstimulation, hyperprolactinaemia and LH gonadotroph adenoma","volume":"19","author":"Castelo-Branco","year":"2009","journal-title":"Reproductive Biomedicine Online"},{"key":"10.1002\/14651858.CD008605.pub4-BIB0069|cit69","unstructured":"Cochrane Gynaecology and Fertility Group CGF guidance for writing all sections of systematic reviews https:\/\/cgf.cochrane.org\/sites\/cgf.cochrane.org\/files\/public\/uploads\/cgf_guidance_15_oct_2020.pdf"},{"issue":"4","key":"10.1002\/14651858.CD008605.pub4-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/j.1479-828X.2012.01448.x","article-title":"Treatment of infertility in polycystic ovary syndrome: a brief update","volume":"52","author":"Costello","year":"2012","journal-title":"Australian & New Zealand Journal of Obstetrics & Gynaecology"},{"issue":"3","key":"10.1002\/14651858.CD008605.pub4-BIB0071|cit71","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002806.pub2","article-title":"Embryo freezing for preventing ovarian hyperstimulation syndrome","author":"D'Angelo","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD008605.pub4-BIB0072|cit72","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002811","article-title":"Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome","author":"D'Angelo","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD008605.pub4-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1093\/humupd\/8.3.291","article-title":"A qualitative systematic review of coasting, a procedure to avoid ovarian hyperstimulation syndrome in IVF patients","volume":"18","author":"Delvigne","year":"2002","journal-title":"Human Reproduction Update"},{"issue":"1","key":"10.1002\/14651858.CD008605.pub4-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S1472-6483(10)60699-2","article-title":"IVF, IVM, natural cycle IVF, minimal stimulation IVF - time for a rethink","volume":"15","author":"Edwards","year":"2007","journal-title":"Reproductive Biomedicine Online"},{"key":"10.1002\/14651858.CD008605.pub4-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1517\/14712598.3.2.263","article-title":"VEGF blocking therapy in the treatment of cancer","volume":"3","author":"Glade-Bender","year":"2003","journal-title":"Expert Opinion on Biological Therapy"},{"issue":"6","key":"10.1002\/14651858.CD008605.pub4-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1097\/00006254-198906000-00004","article-title":"Ovarian hyperstimulation syndrome: an update review","volume":"44","author":"Golan","year":"1989","journal-title":"Obstetrical & Gynecological Survey"},{"key":"10.1002\/14651858.CD008605.pub4-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1210\/en.2002-220204","article-title":"Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rats, and this effect is prevented by receptor blockade","volume":"143","author":"G\u00f3mez","year":"2002","journal-title":"Endocrinology"},{"key":"10.1002\/14651858.CD008605.pub4-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"5400","DOI":"10.1210\/en.2006-0657","article-title":"Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model","volume":"147","author":"G\u00f3mez","year":"2006","journal-title":"Endocrinology"},{"key":"10.1002\/14651858.CD008605.pub4-BIB0079|cit79","unstructured":"GRADE Working Group McMaster University GRADEpro GDT: GRADEpro Guideline Development Tool [Software] gradepro.org"},{"key":"10.1002\/14651858.CD008605.pub4-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"19093","DOI":"10.1038\/srep19093","article-title":"Pharmacologic interventions in preventing ovarian hyperstimulation syndrome: a systematic review and network meta-analysis","volume":"6","author":"Guo","year":"2016","journal-title":"Scientific Reports"},{"key":"10.1002\/14651858.CD008605.pub4-BIB0081|cit81","unstructured":"Higgins JP Green S Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from training.cochrane.org\/handbook\/archive\/v5.1\/"},{"key":"10.1002\/14651858.CD008605.pub4-BIB0082|cit82","doi-asserted-by":"crossref","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Interventions Version 6 (updated July 2019). Cochrane, 2019 Available from training.cochrane.org\/handbook\/archive\/v6","DOI":"10.1002\/9781119536604"},{"issue":"2","key":"10.1002\/14651858.CD008605.pub4-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.fertnstert.2010.03.028","article-title":"Preventing ovarian hyperstimulation syndrome: guidance for the clinician","volume":"94","author":"Humaidan","year":"2010","journal-title":"Fertility and Sterility"},{"issue":"2","key":"10.1002\/14651858.CD008605.pub4-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3109\/09513590.2012.730578","article-title":"Cabergoline as treatment of ovarian hyperstimulation syndrome: a review","volume":"29","author":"Kalampokas","year":"2013","journal-title":"Gynecological Endocrinology"},{"issue":"9","key":"10.1002\/14651858.CD008605.pub4-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1210\/jc.2007-2658","article-title":"Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma","volume":"93","author":"Kars","year":"2008","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"12","key":"10.1002\/14651858.CD008605.pub4-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"845","DOI":"10.3109\/09513590.2014.943716","article-title":"Dopamine agonists in prevention of ovarian hyperstimulation syndrome","volume":"30","author":"Kasum","year":"2014","journal-title":"Gynecological Endocrinology"},{"issue":"3","key":"10.1002\/14651858.CD008605.pub4-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"719 e15","DOI":"10.1016\/j.fertnstert.2006.01.055","article-title":"Effectiveness of treating ovarian hyperstimulation syndrome with cabergoline in two patients with gonadotropin-producing pituitary adenomas","volume":"86","author":"Knoepfelmacher","year":"2006","journal-title":"Fertility and Sterility"},{"key":"10.1002\/14651858.CD008605.pub4-BIB0088|cit88","first-page":"1648","article-title":"Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma","volume":"9","author":"Kuenen","year":"2003","journal-title":"Clinical Cancer Research"},{"issue":"3","key":"10.1002\/14651858.CD008605.pub4-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.fertnstert.2013.11.005","article-title":"Cabergoline for the prevention of ovarian hyperstimulation syndrome: a systematic review and meta-analysis of randomized controlled trials","volume":"101","author":"Leitao","year":"2014","journal-title":"Fertility and Sterility"},{"issue":"1","key":"10.1002\/14651858.CD008605.pub4-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ejogrb.2005.01.009","article-title":"Cabergoline: a safe, easy, cheap, and effective drug for prevention\/treatment of ovarian hyperstimulation syndrome?","volume":"122","author":"Manno","year":"2005","journal-title":"European Journal of Obstetrics, Gynecology, and Reproductive Biology"},{"key":"10.1002\/14651858.CD008605.pub4-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"b381","DOI":"10.1136\/bmj.b381","article-title":"Dopamine agonists and hyperprolactinaemia","volume":"338","author":"Martin","year":"2009","journal-title":"BMJ"},{"issue":"2","key":"10.1002\/14651858.CD008605.pub4-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1080\/14647270601111239","article-title":"Review of the evidence base of strategies to prevent ovarian hyperstimulation syndrome","volume":"10","author":"Mathur","year":"2007","journal-title":"Human Fertility"},{"key":"10.1002\/14651858.CD008605.pub4-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1210\/en.2004-0765","article-title":"The vascular endothelial growth factor (VEGF)\/VEGF receptor 2 pathway is critical for blood vessel survival in corpora lutea of pregnancy in the rodent","volume":"146","author":"Pauli","year":"2005","journal-title":"Endocrinology"},{"issue":"9","key":"10.1002\/14651858.CD008605.pub4-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ogrm.2009.05.003","article-title":"Ovarian hyperstimulation syndrome: pathophysiology, prevention and management","volume":"19","author":"Prakash","year":"2009","journal-title":"Obstetrics, Gynaecology and Reproductive Medicine"},{"issue":"1","key":"10.1002\/14651858.CD008605.pub4-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/0002-9378(67)90137-8","article-title":"Human menopausal gonadotropins for anovulation and sterility. Results of 7 years of treatment","volume":"98","author":"Rabau","year":"1967","journal-title":"American Journal of Obstetrics and Gynecology"},{"key":"10.1002\/14651858.CD008605.pub4-BIB0096|cit96","unstructured":"Royal College of Obstetricians and Gynaecologists (RCOG) The management of ovarian hyperstimulation syndrome London (UK): Royal College of Obstetricians and Gynaecologists (RCOG). Green-top Guideline No 5 2006"},{"key":"10.1002\/14651858.CD008605.pub4-BIB0097|cit97","unstructured":"Review Manager (RevMan) Nordic Cochrane Centre, The Cochrane Collaboration 2014"},{"key":"10.1002\/14651858.CD008605.pub4-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1095\/biolreprod.102.006700","article-title":"Inhibition of vascular endothelial growth factor\/vascular permeability factor action blocks estrogen-induced uterine edema and implantation in rodents","volume":"67","author":"Rockwell","year":"2002","journal-title":"Biology of Reproduction"},{"key":"10.1002\/14651858.CD008605.pub4-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa062222","article-title":"Dopamine agonists and the risk of cardiac-valve regurgitation","volume":"356","author":"Schade","year":"2007","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD008605.pub4-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/humupd\/dmn008","article-title":"Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome","volume":"14","author":"Soares","year":"2008","journal-title":"Human Reproduction Update"},{"issue":"3","key":"10.1002\/14651858.CD008605.pub4-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.fertnstert.2011.12.046","article-title":"Etiology of OHSS and use of dopamine agonists","volume":"97","author":"Soares","year":"2012","journal-title":"Fertility and Sterility"},{"key":"10.1002\/14651858.CD008605.pub4-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2165\/11594940-000000000-00000","article-title":"Risk of cardiac valve regurgitation with dopamine agonist use in Parkinson's disease and hyperprolactinaemia: a multi-country, nested case-control study","volume":"35","author":"Trifiro","year":"2012","journal-title":"Drug Safety"},{"issue":"11","key":"10.1002\/14651858.CD008605.pub4-BIB0103|cit103","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006105.pub3","article-title":"Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome","author":"Tso","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD008605.pub4-BIB0104|cit104","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009154.pub3","article-title":"Luteal phase support for assisted reproduction cycles","author":"Linden","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD008605.pub4-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.bpobgyn.2009.02.006","article-title":"Ovarian hyperstimulation syndrome and complications of ART","volume":"23","author":"Vloeberghs","year":"2009","journal-title":"Best Practice & Research. Clinical Obstetrics & Gynaecology"},{"issue":"6","key":"10.1002\/14651858.CD008605.pub4-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.rbmo.2012.08.001","article-title":"IVF versus ICSI for the fertilization of in-vitro matured human oocytes","volume":"25","author":"Walls","year":"2012","journal-title":"Reproductive Biomedicine Online"},{"issue":"1","key":"10.1002\/14651858.CD008605.pub4-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1093\/humrep\/deu248","article-title":"In vitro maturation as an alternative to standard in vitro fertilization for patients diagnosed with polycystic ovaries: a comparative analysis of fresh, frozen and cumulative cycle outcomes","volume":"30","author":"Walls","year":"2015","journal-title":"Human Reproduction"},{"issue":"5","key":"10.1002\/14651858.CD008605.pub4-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1093\/humupd\/dmq006","article-title":"Can dopamine agonists reduce the incidence and severity of OHSS in IVF\/ICSI treatment cycles? A systematic review and meta-analysis","volume":"16","author":"Youssef","year":"2010","journal-title":"Human Reproduction Update"},{"issue":"8","key":"10.1002\/14651858.CD008605.pub4-BIB0109|cit109","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001302","article-title":"Volume expanders for the prevention of ovarian hyperstimulation syndrome","author":"Youssef","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD008605.pub4-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMoa054830","article-title":"Valvular heart disease and the use of dopamine agonists for Parkinson's disease","volume":"356","author":"Zanettini","year":"2007","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD008605.pub4-BIB0111|cit111","doi-asserted-by":"crossref","unstructured":"Dopamine agonists for preventing ovarian hyperstimulation syndrome Cochrane Database of Systematic Reviews 2016 11 10.1002\/14651858.CD008605.pub3","DOI":"10.1002\/14651858.CD001302.pub3"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T07:45:59Z","timestamp":1684395959000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD008605.pub4"}},"subtitle":[],"editor":[{"name":"Cochrane Gynaecology and Fertility Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,4,14]]},"references-count":111,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,4]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd008605.pub4","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,14]]}}}